文献速递帕金森病与运动障碍

荟萃分析识别帕金森病中差异表达的microRNA

Meta-analyses identify differentially expressed micrornas in Parkinson's disease.
PubMed 文献 · Ann Neurol · 2019-01-01

该研究系统检索帕金森病(PD)microRNA表达研究,对脑、血、脑脊液(CSF)标本进行荟萃分析,共47个数据集纳入160项荟萃分析。在脑(3个)和血(10个)中鉴定出13个显著差异表达且方向一致的miRNA,CSF中无显著信号;脑miRNA靶基因的GWAS变异在9个位点显著关联。

要点

  • 脑和血中分别有3个和10个miRNA在PD中差异表达一致。
  • 血液hsa-miR-221-3p、hsa-miR-214-3p等差异高度显著。
  • 脑miRNA靶基因的遗传变异在9个位点与PD显著关联。

核心结论

  • 在帕金森病脑和血中鉴定出多个高度显著差异表达的miRNA,CSF中无显著发现。

研究设计与样本

  • 系统文献检索miRNA表达研究,按脑、血、CSF分层,对3个以上独立数据集评估的miRNA进行荟萃分析。
  • 筛选599篇出版物后,47个数据集纳入分析,共进行160项荟萃分析(脑125、血31、CSF4)。

主要发现

  • 脑和血中共13个miRNA显著差异表达(Bonferroni校正α=3.13×10-4),方向一致。
  • 脑中最突出:hsa-miR-132-3p(p=6.37×10-5)、hsa-miR-497-5p(p=1.35×10-4)、hsa-miR-133b(p=1.90×10-4)。
  • 血中最突出:hsa-miR-221-3p(p=4.49×10-35)、hsa-miR-214-3p(p=2.00×10-34)、hsa-miR-29c-3p(p=3.00×10-12)。
  • CSF中未发现显著信号。
  • 脑miRNA靶基因的GWAS数据在9个位点显示显著关联(α=9.40×10-5)。

关键数值与推荐

  • 差异表达显著性阈值:Bonferroni校正α=3.13×10-4。
  • 脑miRNA靶基因GWAS关联显著性阈值:α=9.40×10-5。

临床怎么用

  • 脑miRNA可能参与PD发病和疾病进展,值得进一步机制研究。
  • 顶级血液miRNA有潜力作为PD诊断、进展或预测的生物标志物。

局限性

  • CSF分析仅4项荟萃分析,未发现显著信号,证据有限。
  • 研究基于已发表数据集,可能存在异质性和发表偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: MicroRNA (miRNA)-mediated (dys)regulation of gene expression has been implicated in Parkinson's disease (PD), although results of miRNA expression studies remain inconclusive. We aimed to identify miRNAs that show consistent differential expression across all published expression studies in PD. METHODS: We performed a systematic literature search on miRNA expression studies in PD and extracted data from eligible publications. After stratification for brain, blood, and cerebrospinal fluid (CSF)-derived specimen, we performed meta-analyses across miRNAs assessed in three or more independent data sets. Meta-analyses were performed using effect-size- and p-value-based methods, as applicable. RESULTS: After screening 599 publications, we identified 47 data sets eligible for meta-analysis. On these, we performed 160 meta-analyses on miRNAs quantified in brain (n = 125), blood (n = 31), or CSF (n = 4). Twenty-one meta-analyses were performed using effect sizes. We identified 13 significantly (Bonferroni-adjusted α = 3.13 × 10-4 ) differentially expressed miRNAs in brain (n = 3) and blood (n = 10) with consistent effect directions across studies. The most compelling findings were with hsa-miR-132-3p (p = 6.37 × 10-5 ), hsa-miR-497-5p (p = 1.35 × 10-4 ), and hsa-miR-133b (p = 1.90 × 10-4 ) in brain and with hsa-miR-221-3p (p = 4.49 × 10-35 ), hsa-miR-214-3p (p = 2.00 × 10-34 ), and hsa-miR-29c-3p (p = 3.00 × 10-12 ) in blood. No significant signals were found in CSF. Analyses of genome-wide association study data for target genes of brain miRNAs showed significant association (α = 9.40 × 10-5 ) of genetic variants in nine loci. INTERPRETATION: We identified several miRNAs that showed highly significant differential expression in PD. Future studies may assess the possible role of the identified brain miRNAs in pathogenesis and disease progression as well as the potential of the top blood miRNAs as biomarkers for diagnosis, progression, or prediction of PD. ANN NEUROL 2019;85:835-851.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Schulz J, Takousis P, Wohlers I, et al. Meta-analyses identify differentially expressed micrornas in Parkinson's disease. Ann Neurol. 2019. PMID: 30990912. doi:10.1002/ana.25490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。